company background image
688266 logo

Suzhou Zelgen BiopharmaceuticalsLtd SHSE:688266 Stock Report

Last Price

CN¥118.86

Market Cap

CN¥31.5b

7D

3.1%

1Y

110.4%

Updated

10 Jun, 2025

Data

Company Financials +

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

SHSE:688266 Stock Report

Market Cap: CN¥31.5b

688266 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Suzhou Zelgen BiopharmaceuticalsLtd
Historical stock prices
Current Share PriceCN¥118.86
52 Week HighCN¥123.37
52 Week LowCN¥49.00
Beta0.32
1 Month Change19.47%
3 Month Change34.29%
1 Year Change110.45%
3 Year Change232.10%
5 Year Change45.31%
Change since IPO59.35%

Recent News & Updates

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Mar 03
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Recent updates

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Mar 03
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Is Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) Using Debt Sensibly?

Jan 23
Is Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) Using Debt Sensibly?

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors

Nov 27
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors

Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates

Sep 11
Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates

What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates

May 08
What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up

Mar 06
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up

Shareholder Returns

688266CN BiotechsCN Market
7D3.1%3.8%2.2%
1Y110.4%8.8%15.2%

Return vs Industry: 688266 exceeded the CN Biotechs industry which returned 8.8% over the past year.

Return vs Market: 688266 exceeded the CN Market which returned 15.2% over the past year.

Price Volatility

Is 688266's price volatile compared to industry and market?
688266 volatility
688266 Average Weekly Movement8.6%
Biotechs Industry Average Movement6.4%
Market Average Movement6.7%
10% most volatile stocks in CN Market9.9%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 688266's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 688266's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
2009910Zelin Shengwww.zelgen.com

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Fundamentals Summary

How do Suzhou Zelgen BiopharmaceuticalsLtd's earnings and revenue compare to its market cap?
688266 fundamental statistics
Market capCN¥31.46b
Earnings (TTM)-CN¥126.59m
Revenue (TTM)CN¥592.35m
53.1x
P/S Ratio
-248.5x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688266 income statement (TTM)
RevenueCN¥592.35m
Cost of RevenueCN¥50.04m
Gross ProfitCN¥542.31m
Other ExpensesCN¥668.90m
Earnings-CN¥126.59m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.48
Gross Margin91.55%
Net Profit Margin-21.37%
Debt/Equity Ratio81.0%

How did 688266 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/10 19:48
End of Day Share Price 2025/06/10 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyu HeChina International Capital Corporation Limited
Shitong HanCitic Securities Co., Ltd.
Yinhao TangCitic Securities Co., Ltd.